Inceptionr LLC Makes New $351,000 Investment in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Inceptionr LLC purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 15,491 shares of the life sciences company’s stock, valued at approximately $351,000.

A number of other hedge funds also recently bought and sold shares of the business. KBC Group NV boosted its position in Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Integra LifeSciences by 4.1% during the fourth quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock valued at $2,919,000 after acquiring an additional 5,032 shares during the last quarter. Choreo LLC raised its holdings in shares of Integra LifeSciences by 29.9% during the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company’s stock valued at $500,000 after acquiring an additional 5,123 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of Integra LifeSciences during the fourth quarter valued at approximately $180,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley started coverage on Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price for the company. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $23.00 on Monday. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $36.80. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market cap of $1.78 billion, a PE ratio of -255.53, a P/E/G ratio of 0.73 and a beta of 1.23. The stock has a 50 day moving average price of $23.79 and a 200 day moving average price of $21.90.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter last year, the firm earned $0.89 earnings per share. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. Equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.